Valentine P J, Devore B P, Heffron F
Department of Molecular Microbiology and Immunology, Oregon Health Sciences University, Portland, Oregon, USA.
Infect Immun. 1998 Jul;66(7):3378-83. doi: 10.1128/IAI.66.7.3378-3383.1998.
A panel of Salmonella typhimurium 14028s mutants, which were previously shown to be highly attenuated in the BALB/c mouse model of infection, were analyzed for their potential as live Salmonella oral-vaccine candidates. A prototypical aroA mutant was chosen as a basis of comparison. From the panel of mutants initially chosen for this study, three mutants with comparable levels of attenuation elicited higher Salmonella-specific serum immunoglobulin G (IgG) and/or mucosal secretory-IgA antibody titers than the aroA vaccine strain. The three mutants, CL288, CL401, and CL554, also elicited a better protective immune response than the aroA control strain, after a single oral dose of 1 x 10(9) to 2 x 10(9) bacteria.
一组鼠伤寒沙门氏菌14028s突变体，先前已证明其在BALB/c小鼠感染模型中高度减毒，对其作为活沙门氏菌口服疫苗候选物的潜力进行了分析。选择了一个典型的aroA突变体作为比较基础。从最初为本研究选择的突变体组中，三个减毒水平相当的突变体诱导产生的沙门氏菌特异性血清免疫球蛋白G（IgG）和/或粘膜分泌型IgA抗体滴度高于aroA疫苗株。在口服单剂量1×10⁹至2×10⁹个细菌后，这三个突变体CL288、CL401和CL554也诱导产生了比aroA对照株更好的保护性免疫反应。
